Investigation of therapeutic effects and mechanisms of Shenqi Buqi Granules on patients with chronic heart failure of Qi deficiency based on proteomics.
10.19540/j.cnki.cjcmm.20250314.502
- Author:
Zhi-Bo WANG
1
;
Ying LI
1
;
Lan MIAO
1
;
Jun-Guo REN
1
;
Jian-Xun LIU
1
Author Information
1. Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
- Publication Type:Journal Article
- Keywords:
CD34;
PPP1CA;
Shenqi Buqi Granules;
chronic heart failure of Qi deficiency;
proteomics;
traditional Chinese medicine
- MeSH:
Humans;
Drugs, Chinese Herbal/therapeutic use*;
Heart Failure/metabolism*;
Male;
Female;
Proteomics;
Middle Aged;
Qi;
Aged;
Protein Interaction Maps/drug effects*;
Adult;
Chronic Disease
- From:
China Journal of Chinese Materia Medica
2025;50(11):3168-3179
- CountryChina
- Language:Chinese
-
Abstract:
This study explored the efficacy and mechanisms of Shenqi Buqi Granules in treating chronic heart failure(CHF) of Qi deficiency using proteomics and bioinformatics methods. A total of 18 healthy participants(health group) and 19 patients with Qi deficiency-type CHF(experimental group) were enrolled and treated with Shenqi Buqi Granules for 12 weeks. Clinical indicators, including Qi deficiency scores, complete blood count, biochemical parameters, lipid profiles, and cardiac function, were collected from pre-and post-experimental groups. Serum proteomics analysis was performed. Differential proteins were screened through differential analysis and K-means clustering. Further analyses, including subcellular localization, Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment, and protein-protein interaction(PPI) network construction, were conducted to identify pathways and proteins associated with Shenqi Buqi Granules treatment. Spearman correlation analysis focused on proteins most correlated with the core phenotype of CHF of Qi deficiency. The results show that Shenqi Buqi Granules treatment reduced Qi deficiency scores and brain natriuretic peptide levels of pre-experimental group. A total of 1 594 proteins were quantified in the proteomics analysis, with 98 proteins showing differential expression between healthy group and experimental group before and after treatment. Subcellular localization analysis revealed 6 protein sources, while KEGG pathway enrichment highlighted biological processes including angiogenesis, immune inflammation, calcium homeostasis, cytoskeletal regulation, protein synthesis, and energy metabolism. Core genes identified included CD34, CSF1, CALM1, CALML3, PPP1CA, PFN1, and 3 ribosomal large subunit proteins. Correlation analysis between core proteins and Qi deficiency scores revealed that CD34(r=-0.67, P<0.05) and PPP1CA(r=0.62, P<0.01) were most strongly associated with Qi deficiency scores. This study suggests that Shenqi Buqi Granules improves Qi deficiency scores and CHF symptoms by regulating angiogenesis, immune inflammation, calcium homeostasis, cytoskeletal regulation, protein synthesis, and energy metabolism. CD34 and PPP1CA are identified as core proteins involved in the therapeutic effects of Shenqi Buqi Granules on Qi deficiency.
